NEW YORK, Sept. 22, 2016 /PRNewswire-USNewswire/ -- Members of the Department of Radiation Oncology at Montefiore Einstein
"For too long people with pancreatic cancer have faced poor prognoses, with immunotherapies offering little hope," said Shalom Kalnicki, M.D., professor and chair, Department of Radiation Oncology, Montefiore-Einstein. "By combining radiation therapy and immunotherapy we have obtained promising results that indicate that we can change how the body reacts to cancer cells and that we have the potential to enhance the effectiveness of immunotherapies in fighting diseases that are difficult to treat. We are excited about this progress, which we believe represents the future of effective cancer therapies. We look forward to sharing these findings and presenting new recommendations for effectively treating several cancers."
Following are the oral presentations Montefiore-Einstein investigators will deliver at the meeting, which are embargoed until the time of presentation. Additionally, Dr. Kalnicki will be one of ten individuals honored with the ASTRO Fellows designation for his significant contributions to the field of radiation oncology and improving patient outcomes.
Investigators are available for interviews specific to their presentation or to comment on other reports of interest at ASTRO 2016.
1. Epigenetic Priming and High-Dose Radiation for Enhanced Immune Response in Pancreatic Cancer – Presented by Kartik Mani, M.D., Ph.D., chief resident, Department of Radiation Oncology, Montefiore Einstein Center for Cancer Care. Tuesday, September 27 at 2:55pm. Biology Track – Room #257 A/B – Presentation 196.
2. Radiation Therapy Compliance/Quality Assurance (QA) in Two Phase II Trials of Cetuximab Plus Combined Modality Therapy (CMT) including Chemotherapy and Radiation Therapy (RT) for Squamous Cell Carcinoma of the Anal Cancer (SCCAC) in Patients with (AMC045) – Presented by Madhur Garg, M.D., clinical director, Department of Radiation Oncology, Montefiore Einstein Center for Cancer Care and professor of clinical radiation oncology at Einstein. Tuesday, September 27 at 5:15pm. Gastrointestinal Track – Room #160 A/B/C – Presentation 239
3. Patterns of Failure and Origin of Recurrence on PET/CT for Laryngeal Cancer Patients Treated with Definitive IMRT– Discussion led by Rafi Kabarriti, M.D., attending physician, Department of Radiation Oncology, Montefiore Einstein Center for Cancer Care and assistant professor of radiation oncology at Einstein. Wednesday, September 28 at 11:00am. Physics Track – Room #052 B – Presentation 1135.
About Montefiore Health SystemMontefiore Health System is one of New York's premier academic health systems and is a recognized leader in providing exceptional quality and personalized, accountable care to approximately three million people in communities across the Bronx, Westchester and the Hudson Valley. It is comprised of 10 hospitals, including the Children's Hospital at Montefiore, Burke Rehabilitation Hospital and close to 200 outpatient care sites. The advanced clinical and translational research at its' medical school, Albert Einstein College of Medicine, directly informs patient care and improves outcomes. From the Montefiore-Einstein Centers of Excellence in cancer, cardiology and vascular care, pediatrics, and transplantation, to its' preeminent school-based health program, Montefiore is a fully integrated healthcare delivery system providing coordinated, comprehensive care to patients and their families. For more information please visit www.montefiore.org. Follow us on Twitter and view us on Facebook and YouTube.
About Albert Einstein College of MedicineAlbert Einstein College of Medicine is one of the nation's premier centers for research, medical education and clinical investigation. During the 2015-2016 academic year, Einstein is home to 731 M.D. students, 193 Ph.D. students, 106 students in the combined M.D./Ph.D. program, and 278 postdoctoral research fellows. The College of Medicine has more than 1,900 full-time faculty members located on the main campus and at its clinical affiliates. In 2015, Einstein received $148 million in awards from the National Institutes of Health (NIH). This includes the funding of major research centers at Einstein in aging, intellectual development disorders, diabetes, cancer, clinical and translational research, liver disease, and AIDS. Other areas where the College of Medicine is concentrating its efforts include developmental brain research, neuroscience, cardiac disease, and initiatives to reduce and eliminate ethnic and racial health disparities. Its partnership with Montefiore Medical Center, the University Hospital and academic medical center for Einstein, advances clinical and translational research to accelerate the pace at which new discoveries become the treatments and therapies that benefit patients. Through its extensive affiliation network involving Montefiore, Jacobi Medical Center—Einstein's founding hospital, and three other hospital systems in the Bronx, Brooklyn and on Long Island, Einstein runs one of the largest residency and fellowship training programs in the medical and dental professions in the United States. For more information, please visit www.einstein.yu.edu, read our blog, follow us on Twitter, like us on Facebook, and view us on YouTube.
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/montefiore-and-einstein-investigators-deliver-new-hope-for-treating-deadly-cancers-300332631.html
SOURCE Montefiore Health System
Subscribe to our Free Newsletters!
Yellow fever is a hemorrhagic fever that is transmitted by infected mosquitoes and it can lead to ...
Routes of drug administration play a major role in a medical treatment. Selecting a right route of ...
Spinal anesthesia and epidural anesthesia are types of regional anesthesia in which when a drug is ...View All